

## **Pharmacy Drug Policy Checklist**

POLICY NAME Alopecia Areata Products POLICY #

## Criteria

Exclusion Criteria – Any of the following prevents coverage	
	2.2 Cannot be used in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants
Cov	avaga Cuitavia
COV	erage Criteria
	1.1 Diagnosis of severe alopecia areata defined as Severity of Alopecia Tool (SALT) score of ≥50 indicating at least 50% hair loss
	1.2 Age 18 years or older for Olumiant, age 12 years or older for Litfulo
	1.3 Current alopecia episode lasting at least 6 months without spontaneous regrowth
	1.4 Prescribed by or in consultation with a dermatologist (skin doctor)
	1.5 Documented trial and failure to one of the following therapies or clinical contraindication to all:
	<ul> <li>Oral (by mouth), intralesional (injection) or topical (applied to skin) corticosteroid</li> </ul>
	<ul> <li>Topical (applied to the skin) immunotherapy (such as diphenylcyclopropenone or squaric acid dibutyl ester)</li> </ul>
	• Conventional oral (by mouth) immunosuppressant (such as methotrexate or azathioprine)